Pathogenic and Therapeutic Aspects on Dyslipoproteinemia in Renal Insufficiency |
Contents
Abbreviations | 6 |
Lipoprotein metabolism in uremia | 15 |
The present study | 23 |
Copyright | |
7 other sections not shown
Common terms and phrases
abnormalities albumin analysis apolipoprotein apolipoprotein CIII associated atherosclerosis blood bovine changes chromatography chronic renal failure circulating Clin Clinical compared correlation curves decrease deficiency dialysis patients disease effects enzyme estimated evidence factor Figure fluorescence intensity folic acid function glucose glycosylation HDL cholesterol HDL cholesterol concentrations healthy controls hemodialysis patients heparin heparin injection hepatic lipase HL activities hypertriglyceridemia increase influence Invest Kidney Int lipase activities lipid lipolysis lipolytic lipoprotein lipase lipoprotein lipase activity LMWH long-term low density lipoprotein mean measured methods moderate months Nephrol Nilsson-Ehle normal particles plasma LPL activities postheparin plasma present study probably protein purified pyridoxine range reaction receptor reduced reference relative reported risk role samples serum concentrations serum HDL cholesterol serum lipid serum triglyceride concentrations shown significant significantly substrate tissue Transplant treatment triglyceride-rich lipoproteins uremia uremic patients vitro VLDL VLDL particles